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Abstract
Impaired L-carnitine uptake correlates with higher blood pressure in adult men, and L-carnitine restores endothelial
function in aortic rings from spontaneously hypertensive rat (SHR). Thus, endothelial dysfunction in hypertension could
result from lower L-carnitine transport in this cell type. L-Carnitine transport is mainly mediated by novel organic cation
transporters 1 (Octn1, Na+-independent) and 2 (Octn2, Na+-dependent); however, their kinetic properties and potential
consequences in hypertension are unknown. We hypothesize that L-carnitine transport kinetic properties will be altered in
aortic endothelium from spontaneously hypertensive rats (SHR). L-Carnitine transport was measured at different
extracellular pH (pHo 5.5–8.5) in the absence or presence of sodium in rat aortic endothelial cells (RAECs) from non-
hypertensive Wistar-Kyoto (WKY) rats and SHR. Octn1 and Octn2 mRNA relative expression was also determined. Dilation of
endothelium-intact or denuded aortic rings in response to calcitonine gene related peptide (CGRP, 0.1–100 nmol/L) was
measured (myography) in the absence or presence of L-carnitine. Total L-carnitine transport was lower in cells from SHR
compared with WKY rats, an effect due to reduced Na+-dependent (Na+dep) compared with Na
+-independent (Na+indep)
transport components. Saturable L-carnitine transport kinetics show maximal velocity (Vmax), without changes in apparent
Km for Na
+
indep transport in SHR compared with WKY rats. Total and Na
+
dep component of transport were increased, but
Na+indep transport was reduced by extracellular alkalization in WKY rats. However, alkalization reduced total and Na
+
indep
transport in cells from SHR. Octn2 mRNA was higher than Octn-1 mRNA expression in cells from both conditions. Dilation of
artery rings in response to CGRP was reduced in vessels from SHR compared with WKY rats. CGRP effect was endothelium-
dependent and restored by L-carnitine. All together these results suggest that reduced L-carnitine transport (likely via Na+-
dependent Octn2) could limit this compound’s potential beneficial effects in RAECs from SHR.
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Introduction
Essential hypertension is characterized by high blood pressure
without an identifiable primary cause [1,2]. Oral administration of
L-carnitine, a natural amino acidic compound, in patients with
hypertension resulted in an improvement of arterial blood
pressure, thus suggesting a beneficial vascular role for this
compound in these subjects [3,4]. Along with the well-described
role of L-carnitine on fatty acid mitochondrial metabolism [5,6],
L-carnitine also increases the metabolic activity in human vascular
endothelium [7,8], and improves the bioavailability of nitric oxide
(NO) in rat aorta [9] and in fetal lamb pulmonary vasculature
[10]. Other studies show that L-carnitine supplementation in
healthy subjects improved postprandial flow-mediated dilation
after a high-fat meal [11]. Taken together, all these findings
suggest that the transport of L-carnitine into the endothelial cells
could be an essential, limiting step of its potential beneficial
biological effects in hypertension.
The uptake of L-carnitine is mediated by novel organic cation
transporters (OCTNs) of which at least three isotypes (rOctn1,
rOctn2 and rOctn3) are expressed in rats [12]. Octn1- an Octn3-
mediated L-carnitine transport is independent of sodium (Na+)
with apparent Michaelis-Menten (Km) values in the range of 2–
200 mmol/L [13–15] and 3–6 mmol/L [16,17], respectively. On
the contrary, Octn2-mediated transport is Na+-dependent with
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apparent Km between 2–20 mmol/L [16,18–23]. Studies per-
formed in spontaneously hypertensive rat (SHR) show that L-
carnitine restores endothelial function in preparations of aortic
rings [24,25], and ameliorates the high-systolic arterial blood
pressure exhibited by hypertensive animals [5,8,26]. Interestingly,
there are no reports addressing the properties of L-carnitine
transport in endothelial cells from SHR. Thus, we hypothesize
that the activity of OCTNs-mediated membrane transport of L-
carnitine by the aortic endothelium is reduced in these hyperten-
sive animals.
The results of this study show that aorta endothelial cells from
SHR exhibit reduced maximal L-carnitine transport capacity
compared with cells from non-hypertensive animals. Transport of
L-carnitine was saturable and mediated by a larger Na+-
independent, Octn1-like compared with a Na+-dependent,
Octn2-like transport activity in these cells from SHR. However,
similar Na+-dependent and Na+-independent transport compo-
nents were found in non-hypertensive rats. It is suggested that the
observed endothelial dysfunction in SHR could be due to reduced
Na+-dependent transport of L-carnitine, which could limit the
potential beneficial effects of this compound in the endothelial
function in hypertension.
Methods
Ethics statement and animals
This investigation strictly conforms to the principles outlined in
the European Union Guidelines on the protection of animals used
for scientific purposes (DIRECTIVE 2010/63/EU of the Euro-
pean Parliament and of the Council). Protocols were approved by
the Committee on the Ethics of Animal Experiments of the
University of Sevilla (Spain). Normotensive male Wistar-Kyoto
(WKY) and spontaneously hypertensive rats (SHR) aged 8 weeks
were obtained from the French Animal Production Center,
JANVIER S.A.S. (Saint Berthevin Cedex, France). Rats were
housed at a temperature of 22–24uC in individual cages and freely
fed (ad libitum) regular pellet diet (12 mm pellet, Harlan
Laboratories, Indianapolis, USA) until they were 10 weeks of
age (wa). They were divided into two groups of 15 animals each,
i.e., WKY (control) and SHR (hypertensive) animals. Character-
ization of WKY rats and SHR in terms of the diastolic and systolic
blood pressures and body weight was determined at arrival of the
animals (8 wa) and at the moment of isolation of aorta endothelial
cells (i.e., 10 wa) as reported [26]. Diastolic and systolic blood
pressure values were not significantly different (P.0.05) at 8 wa
(diastolic = 93 6 3 mmHg, systolic = 123 6 6 mmHg)
compared with 10 wa (diastolic = 95 6 2 mmHg, systolic =
124 6 5 mmHg) in WKY rats. However, these parameters were
elevated (P,0.01) in SHR at 8 wa (diastolic = 190 6 2 mmHg,
systolic = 233 6 2 mmHg) and 10 wa (diastolic = 191 6
2 mmHg, systolic = 231 6 1 mmHg) compared with the
corresponding systolic or diastolic values in WKY rats, but were
not significantly different (P.0.05) between them in SHR.
Cell culture
Aortas from WKY rats and SHR aged 10 weeks were excised
and placed in a petri dish containing phosphate-buffered saline
(PBS) solution ((mmol/L) NaCl 130, KCl 2.7, Na2HPO4 0.8,
KH2PO4 1.4 (pH 7.4, 4uC)). The tissue was rinsed by changing
PBS until free of any visible blood, and the aorta was stripped of
adventicia as reported [27]. Rat aorta endothelial cells (RAECs)
were isolated by scraping of rat aortic lumen in the presence of
medium 199 (M199) (Gibco Life Technologies, Carlsbad, CA,
USA) containing 5 mmol/L D-glucose, 10% new born calf serum,
10% fetal calf serum (FCS) (Gibco), 3.2 mmol/L L-glutamine and
100 U/mL penicillin-streptomycin (primary culture medium,
PCM) (Gibco), and cultured up to passage 3 (37uC, 5% CO2).
Twenty-four hours prior to experiments the incubation medium
was replaced by M199 containing 2% sera after two rinses with
200 mL in PBS (37uC). Cells were used in passage 3 for most of the
experiments. In addition, in some of transport assays confluent
freshly isolated cells (i.e., passage 0) or cells in passages 1 or 2 in
culture were also used.
L-Carnitine transport
Total transport of L-carnitine (TTC) was defined as the result of
the sum of the Na+-dependent (hereafter referred as TTCNa+dep)
and Na+-independent (hereafter referred as TTCNa+indep) compo-
nents plus a nonsaturable, lineal component of transport in the
range of L-carnitine used in this study (hereafter referred as
mN[Car], where m corresponds to slopes of lineal phases of TTC at
each L-carnitine concentrations [Car]) [28]. The TTC (0–
80 mmol/L L-carnitine, 3 mCi/mL L-[3H]carnitine (NEN,
Dreieich, FRG), 30 seconds, 37uC) was measured as previously
described for other amino acids in primary cultured endothelium
[28]. Briefly, TTC assays were performed in a Na+-containing
Krebs ((mmol/L): NaCl 131, KCl 5.6, NaHCO3 25, NaH2PO4 1,
Hepes 20, D-glucose 5, CaCl2 2.5, MgCl2 1 (pH 7.4, 37uC)) or in
Na+-free Krebs solution ((mmol/L) N-methyl-D-glucamine
(NMDG) 120, KCl 5.6, Hepes 20, D-glucose 5, CaCl2 2.5, MgCl2
1 (pH 7.4, 37uC)).
Initial rate for TTC, TTCNa+dep and
TTCNa+indep components was
derived from slopes of lineal phases of 20 mmol/L L-carnitine
transport. Values for L-carnitine transport were adjusted to the
one phase exponential association equation considering the least
squares fit:
vi~Vm. 1{e{(k.t)
 
where vi is initial velocity, Vm is mayor velocity at a given time (t)
and L-carnitine concentration, and e and k are constants.
Data for TTC, TTCNa+dep and
TTCNa+indep components at initial
rates (i.e., linear uptake up to 30 seconds) was adjusted to the
Michaelis-Menten hyperbola plus a nonsaturable, lineal compo-
nent (mN[Car]) as described [28]:
v
Vmax
~
Car½ 
Kmz Car½ z m. Car½ ð Þ
where v is the initial reaction velocity relative to the maximal
velocity (Vmax) and apparent Michaelis-Menten parameter (Km) of
transport at a given L-carnitine concentration ([Car]), m represents
the slope of transport for the range of 0–80 mmol/L L-carnitine
and mN[Car] is the nonsaturable, lineal component of transport in
the range of L-carnitine used in this study [28]. Each assay was run
in duplicate with transport activity expressed as pmol/mg protein/
minute.
After subtracting the mN[Car] component from TTC the
remaining transport was defined as total overall saturable transport
of L-carnitine (TSC). Transport in Na+-free Krebs was considered as
the Na+-independent component of TSC (TSCNa+indep) and the Na
+-
component (TSCNa+dep) was derived from:
TSCNazdep~TSC{
TSCNazindep
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The kinetic parameters Vmax and apparent Km for the TSC,
TSCNa+dep or
TSCNa+indep components were estimating by fitting the
data to the single Michaelis-Menten asymptotic hyperbola
equation:
v
Vmax
~
Car½ 
Kmz Car½ 
Cells were exposed to PCM 2% sera for a period of 2 hours
before the transport assays were performed. Cell viability was
assayed by Trypan blue exclusion and was not significantly altered
(,96% of viable cells) in any experimental condition in this study.
Rinsing the monolayers with ice-cold Krebs with or without Na+
terminated the tracer uptake. Radioactivity in formic acid cell
digests was determined by liquid scintillation counting in an
automated low activity liquid scintillation analyzer (Tri-Carb
2810TR, PerkinElmer, Santa Clara, CA, USA) with efficiency
estimated by converting counts to disintegrations per minute
(d.p.m.) [28]. Uptake of L-[3H]carnitine was corrected for its
extracellular trapping by measuring the accumulation of the non-
transportable D-[14C]mannitol (1 mCi/mL) (PerkinElmer) in the
extracellular space by:
3Hin~
3Hsample{
14Csample.14Cst
3Hst
where 3Hin is the L-[
3H]carnitine associated to the whole cell
extracts, 3Hsample and
14Csample are total L-[
3H]carnitine and D-
[14C]mannitol, respectively, for each sample analysed in the
scintillation counter, and 3Hst and
14Cst are d.p.m. for standards of
L-[3H]carnitine and D-[14C]mannitol, respectively.
The relative contribution of the hypertension exhibited by SHR
to the saturable L-carnitine kinetic parameters (1/F) was estimated
from the maximal transport capacity (Vmax/Km) values for TSC by:
1
WKY=SHRF
~
WKYKm.SHRVmax
WKYVmax.SHRKm
where WKYVmax and
WKYKm are the kinetics parameters for TSC in
cells from WKY rats, and SHRVmax and
SHRKm are kinetics
parameters of transport in cells from SHR. The relative
contribution of the TSCNa+dep or
TSCNa+indep components to TSC
in SHR or WKY rats was estimated from:
1
TSC=XF
~
TSCKm.XVmax
TSCVmmax.XKm
where X represents the TSCNa+dep or
TSCNa+indep components for
the kinetics parameters Vmax and Km of transport compared with
TSC values. The relative contribution of the TSCNa+dep transport
compared with the TSCNa+indep component to L-carnitine transport
in SHR or WKY rats was estimated from:
1
Naz
dep
=Naz
indepF
~
Naz
depKm.
Naz
indepVmax
Naz
depVmax.
Naz
indepKm
Extracellular pH dependency
To assay the effect of extracellular pH (pHo) on TSC,
TSCNa+dep
or TSCNa+indep components of L-carnitine transport (20 mmol/L L-
carnitine, 3 mCi/mL L-[3H]carnitine, 30 seconds, 37uC) the cells
were incubated in Na+-containing or Na+-free Krebs adjusted to a
final pHo of 5.5, 6.5, 7.5 or 8.5 as described [20]. The pHo in the
Na+-containing Krebs solution was adjusted with 1 N HCl or 1 N
NaOH, while the Na+-free Krebs solution was adjusted with 1 N
HCl or 1 N KOH. The pHo values were monitored with a
pHmeter (Oakton Instrument, Vernon Hills, IL, USA) and tracer
uptake was terminated as above.
Isolation of total RNA and reverse transcription
Total RNA was isolated using the Trizol reagent (Invitrogen,
Carlsbad, CA, USA). RNA quality and integrity were insured by
gel visualization and spectrophotometric analysis (OD260/280), and
RNA concentration was determined at 260 nm. Aliquots (1 mg) of
total RNA were reversed transcribed into cDNA as described [28].
RT-PCR
Experiments were performed using a Light Cycler 480
Detection System (Roche Diagnostic, Barcelona, Spain) in a
reaction mix containing 0.5 mmol/L primers and master mix
provided in the brilliant SYBR green qPCR Master Mix
(Stratagene, La Jolla, CA, USA). SecureStart Taq DNA polymer-
ase was activated (15 minutes, 95uC), and assays included a 95uC
denaturation (15 seconds), annealing (20 seconds) at 54uC, and
extension (10 seconds) at 72uC (rOctn1, rOctn2 and GAPDH).
Product melting temperature values were 86uC (rOctn1), 86uC
(rOctn2) and 85uC (GAPDH). Oligonucleotide primers: rOctn1
(sense) 59-TGATAGCCTTCCTGGGCGATTGG-39, rOctn1
(anti-sense) 59-AAGGAGCCACAGAGAACGCCTAC-39, rOctn2
(sense) 59-AGGAGCCCATCAGCACACCCACG-39, rOctn2 (an-
ti-sense) 59-GACGAAGGACGGACGACAGGTGC-39, GAPDH
(sense) 59-GCCAAAAGGGTCATCATCTCCGC-39, GAPDH
(anti-sense) 59-GGATGACCTTGCCCACAGCCTTG-39.
The relative mRNA level in each group was estimated from the
22DDCT method [29]. Data were analyzed using the Light Cycler
480 SW 1.5 relative quantification (delta-delta-Ct) study software
(Roche Diagnostic, Barcelona, Spain) and gene expression levels
were normalized to GAPDH and given as relative fold change
[30]. The GAPDH mRNA level was not significantly altered
(P.0.05, n = 15) in all experimental conditions used in this study
(not shown).
Rat aorta reactivity
Ring segments of 2–4 mm in length were dissected from rat
aorta in cold (4uC) PBS solution. Vessel rings were mounted in a
myograph (610M Multiwire Myograph System, Danish Myo
Technology A/S, Denmark) for isometric force measurements in a
Krebs physiological solution ((mmol/L): NaCl 118.5, KCl 4.7,
NaHCO3 25, MgSO4 1.2, KH2PO4 1.2, CaCl2 2.5, D-glucose 5.5,
300 mmol/L L-arginine, pH 7.4). Artery rings were maintained at
37uC and constantly bubbled with a mixture of 95% O2/5% CO2.
The optimal diameter for each vessel was adjusted through the
determination of the maximal active response evoked by
62.5 mmol/L KCl [28]. Isometric force was measured in response
to calcitonine gene related peptide (CGRP, 0.1–100 nmol/L, 5
minutes) (Peptides International, Inc., KY, USA) in 32.5 mmol/L
KCl preconstricted vessels, in the absence or presence of 20 mmol/
L L-carnitine (30 minutes). In some artery rings, the endothelium
was removed by gentle abrasion of the intimal surface. Successful
removal of this cell layer was determined by a reduction in the
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vasodilatation to CGRP. Changes in isometric tension were
recorded using the software LabChart (LabChart 7 for Windows,
ADInstruments, Australia) coupled to a PowerLab (PowerLab 8/
30 Data Acquisition System, ADIntruments, Australia). The tissue
responses are as a percentage of maximal contraction induced by
62.5 mM KCl.
Statistical analysis
Values are mean 6 SEM, where n indicates the number of
different cell cultures (3–4 replicates). Data reported in this study
describe a normal standard distribution and comparison between
two or more than two groups were performed by means of
Student’s unpaired t-test and analysis of variance (2-way
ANOVA), respectively. If the ANOVA demonstrated a significant
interaction between variables, post hoc analyses were performed
by the multiple-comparison Bonferroni correction test. The
statistical software GraphPad Instat 3.0b and Graphpad Prism
6.0d (GraphPad Software Inc., San Diego, CA, USA) were used
for data analysis. P,0.05 was considered statistically significant.
Results
Overall transport of L-carnitine
The TTC for 20 mmol/L L-carnitine was lower (4468%) in
RAECs from SHR compared with WKY rats (Fig. 1a). TTC
exhibited a TTCNa+dep and a
TTCNa+indep component in cells from
both SHR and WKY rats. However, in cells from WKY rats the
contribution of the TTCNa+dep (5266%) and
TTCNa+indep (6067%)
components to the TTC were similar (P.0.05), whereas, TTC in
cells from SHR resulted from a major contribution of the
TTCNa+indep (8466%) compared with the
TTCNa+dep (2565%)
component of transport (Fig. 1a). Cells in passage 0 (Fig. 1b), 1
(Fig. 1c) or 2 (Fig. 1d) exhibited similar changes in L-carnitine
transport compared with cells in passage 3 (Fig. 1a).
Figure 1. Transport of L-carnitine in RAECs. Total, Na+-dependent (Na+dep) and Na
+-independent (Na+indep) L-carnitine transport (20 mmol/L,
3 mCi/mL L-[3H]carnitine, 30 seconds, 37uC) in RAECs from WKY rats or SHR. Transport was assayed in RAECs in passage 3 (P3) (a) and compared with
cells in passages 0 (P0) (b), 1 (P1) (c) or 2 (P2) (d). *P,0.05 versus all other values, {P,0.05 versus corresponding Na+dep values in SHR, `P,0.05 versus
all other values in SHR. Values are mean 6 SEM (n = 7–20).
doi:10.1371/journal.pone.0090339.g001
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The TTC was lineal up to 40 seconds incubation (Fig. 2a) with vi
values lower in SHR compared with WKY rats (Table 1). In cells
from either SHR or WKY rats the vi for the
TTCNa+indep compared
with the corresponding TTCNa+dep component was higher for
20 mmol/L L-carnitine transport. However, the difference be-
tween the vi for the
TTCNa+indep compared with
TTCNa+dep
component was higher (2.160.3 fold) in cells from SHR compared
with WKY rats (Fig. 2b).
L-Carnitine transport kinetics
The TTC was semisaturable in RAECs from either SHR or
WKY rats (Fig. 3a,b). The KD value for TTC was similar to that for
the TTCNa+indep component of transport in cells from WKY rats;
however, the KD for
TTCNa+dep transport in cells from these animals
and all other KD values in SHR were negligible (Table 1). The
TTCNa+dep and
TTCNa+indep components derived from TTC were
saturable in both groups of cells. The Eadie-Hofstee plot of TTC
data was best fitted by an exponential one phase decay equation
resulting in a non-linear plot in cells from WKY rats (Fig. 3c).
However, the TTCNa+dep and
TTCNa+indep components derived from
TTC in WKY rats were linear (Fig. 3c), as were TTC, TTCNa+dep
and TTCNa+indep components of transport in SHR (Fig. 3d).
After subtracting the lineal, non-saturable component of
transport data (in the range of concentrations used in this study),
the saturable transport for each condition was obtained (Fig. 4a,b).
Cells from SHR exhibit reduced Vmax, but unaltered apparent Km
for TSC compared with cells from WKY rats (Table 1). The Vmax
for the TSCNa+dep, but not for
TSCNa+indep components of transport
was reduced in cells from SHR compared with the corresponding
values in WKY rats. In addition, the Vmax for the
TSCNa+indep
component was higher than TSCNa+dep component of transport
only in SHR (Table 1). The Eadie-Hofstee plot of saturable
transport data was lineal for all experimental conditions (Fig. 4c,d).
The Vmax/Km values for sturable transport and the Na
+
dep
component were lower in SHR compared with WKY rats, and
the value for the TSCNa+dep component was lower than the
TSCNa+indep component of transport in cells from SHR or WKY
rats (Table 1).
Figure 2. Initial velocities for total transport of L-carnitine. (a)
Initial velocity (ni) for total transport of L-carnitine (Total), and the Na
+-
dependent (Na+dep) and Na
+-independent (Na+indep) transport compo-
nents (20 mmol/L L-carnitine, 3 mCi/mL L-[3H]carnitine, 37uC) in RAECs
cultured from WKY rats or SHR. (b) Difference between the vi (Dvi) for
Na+indep and Na
+
dep components of transport in WKY rats or SHR.
*P,0.05 versus WKY. Values are mean 6 SEM (n = 15).
doi:10.1371/journal.pone.0090339.g002
Table 1. Kinetic parameters for transport of L-carnitine in rat aortic endothelial cells.
L-Carnitine transport
WKY SHR
Total Na+dep Na
+
indep Total Na
+
dep Na
+
indep
TTC
vi 0.00760.0001 0.00360.002 0.00460.0003{ 0.00460.0001* 0.00160.0001* 0.00360.0001{
KD 0.001660.0002 ,10
213 0.001360.0013 ,10213 ,10215 ,10214
TSC
Vmax 0.8460.2 0.4260.06 0.4660.2 0.5960.07* 0.2060.03* 0.3260.08{
Km 2869 46619 2164 3068 31611 22616
Vmax/Km 0.03060.008 0.00960.002 0.02260.009{ 0.02060.004* 0.00660.002* 0.01560.007{
Total (TTC) and saturable (TSC) transport of L-carnitine and the Na+-dependent (Na+dep) and Na
+-independent (Na+indep) components of transport (0–80 mmol/L L-
carnitine, 3 mCi/mL L-[3H]carnitine, 30 seconds, 37uC, pH 7.4) were measured in cultured (passage 2) rat aortic endothelial cells (RAECs) from normotensive (WKY) or
spontaneously hypertensive (SHR) rats as described in Methods. The initial velocity (vi) was measured for 20 mmol/L L-carnitine up to 30 seconds. vi, initial velocity
(pmol/mg protein/second); Vmax, maximal velocity (pmol/mg protein/minute); Km, apparent Michaelis-Menten constant (mmol/L); Vmax/Km, maximal transport capacity
(pmol/mg protein/minute/(mmol/L)); KD, lineal, non-saturable transport in the range of L-carnitine concentrations used in this study (pmol/mg protein/minute/(mmol/L)).
*P,0.05 versus corresponding values in WKY, {P,0.05 versus corresponding values for Na+dep in SHR or WKY rats. Values are mean 6 SEM (n = 15).
doi:10.1371/journal.pone.0090339.t001
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Expression of rOctn1 and rOctn2 mRNA
The relative expression of rOctn2 was higher than rOctn1
mRNA in RAECs from SHR or WKY rats (Fig. 5). The relative
mRNA expression of rOctn2 was largely lower in SHR when
compared with WKY; however, no differences were found in
mRNA expression of rOctn1 between cells from these animals.
Extracellular pH dependency on saturable L-carnitine
transport
Overall transport of L-carnitine was higher at pHo 8.5
compared with transport at pHo 7.4, but it was unaltered by
lower pHo values in cells from WKY rats (Fig. 6a). The
TSCNa+indep
component of transport at pHo 7.4 was higher than at pHo 8.5,
but lower than at acidic pHo values. However, the
TSCNa+dep
component of transport at pHo 7.4 was lower than at alkaline, but
higher than at acidic pHo. The half-maximal stimulatory effect
(SE50) of a change in the pHo on overall transport was higher than
the SE50 for the
TSCNa+indep (,0.26 pHo units of difference)
component (Table 2). A similar effect on TSC was seen for the half-
maximal inhibitory effect (IE50) of a change in the pHo on the
TSCNa+dep (,0.53 pHo units of difference) component of transport
in cells from WKY rats (Table 2). In addition, the SE50 for
TSCNa+indep was significantly different from the IE50 for
TSCNa+dep
values (,0.24 pHo units of difference) in these cells.
In RAECs from SHR, the TSC and the TSCNa+indep component
of transport were lower at alkaline pHo compared with transport
at pHo 7.4 (Fig. 6b). However, the
TSCNa+dep component of
saturable transport was unaltered compared with values at
pHo 7.4 in these cell types. The IE50 values for overall and the
TSCNa+indep component of L-carnitine transport (,0.05 pHo units
of difference) were not significantly different in cells from SHR
(Table 2). However, the alkalization required to reduce the overall
transport in cells from SHR was higher (,0.22 pHo units of
difference) compared with the alkalization required to increase the
transport in cells from WKY rats. In addition, the alkalization
required to reduce the TSCNa+indep component of transport in cells
from SHR was higher (,0.93 pHo units of difference) compared
with cells from WKY rats.
Rat aorta reactivity
CGRP caused dilation of preconstricted aortic rings in both
group of animals (Fig. 6c). However, the half-maximal vasodilation
Figure 3. Total transport of L-carnitine kinetics. Total transport of L-carnitine (Total), and the Na+-dependent (Na+dep) and Na
+-independent
(Na+indep) transport components (0–80 mmol/L L-carnitine, 3 mCi/mL L-[
3H]carnitine, 30 seconds, 37uC) in RAECs cultures from WKY rats (a) or SHR (b).
The Eadie-Hofstee plots for transport data in shown for WKY rats (c) and SHR (d) from data in (a) and (b), respectively. Values are mean6 SEM (n = 15).
doi:10.1371/journal.pone.0090339.g003
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(EC50) caused by CGRP was lower in vessels from SHR (EC50 =
9.560.3 nmol/L) compared with WKY (EC50 = 1.060.2 nmol/
L) rats. Supplementation with L-carnitine caused a reduction of
the EC50 for CGRP in vessels from SHR (EC50 = 1.960.3 nmol/
L), but did not alter (P.0.05) this parameter in vessels from WKY
rats (EC50 = 0.960.1 nmol/L). CGRP was ineffective in
endothelium-denuded rat aortic rings (Fig. 6d).
Discussion
We have characterized the kinetics of L-carnitine transport in
primary cultures of rat aortic endothelial cells (RAECs) from non-
hypertensive WKY rats and contrasted this information with cells
from spontaneously hypertensive rats (SHR). Total overall
transport of L-carnitine (TTC) was mediated by Na+-dependent
(TTCNa+dep) and Na
+-independent (TTCNa+indep) components in-
creased by a lineal, nonsaturable mediated transport. A reduced
initial velocity for the TTC and TTCNa+dep, but not the
TTCNa+indep
component was found in cells from SHR compared with non-
hypertensive WKY rats. The kinetics assays for saturable overall
transport of this amino acid (TSC) show that maximal transport
capacity (Vmax/Km) for L-carnitine is lower in cells from SHR
compared with WKY rats, a finding paralleled by reduced Vmax/
Km for the
TSCNa+dep, but not the
TSCNa+indep component. A
differential dependency of pHo for TSC,
TSCNa+dep and
TSCNa+indep
transport was seen in cells from SHR compared with WKY rats.
These results are the first demonstration that RAECs from SHR
exhibit a phenotype characterized by reduced L-carnitine
transport compared with cells from non-hypertensive rats. These
results are potentially useful for a better understanding of the
membrane transport mechanisms of L-carnitine in RAECs from
non-hypertensive WKY rats and SHR. Interestingly, a reduced
reactivity to an endothelium dependent vasodilator of the aortic
rings from SHR compared with WKY rats was seen, an effect that
was improved by supplementation of these vessels in vitro with L-
carnitine. However, vasodilation was absent in endothelium-
denuded aortic ring preparations. It is suggested that a reduced
uptake of L-carnitine by the endothelium could counteract the
reported beneficial vascular effects of L-carnitine supplementation
in subjects with hypertension.
Figure 4. Saturable transport of L-carnitine kinetics. Total saturable transport of L-carnitine (Total), and the Na+-dependent (Na+dep) and Na
+-
independent (Na+indep) transport components (0–80 mmol/L L-carnitine, 3 mCi/mL L-[
3H]carnitine, 30 seconds, 37uC) in RAECs cultures from WKY rats
(a) or SHR (b). The Eadie-Hofstee plots for transport data are shown for WKY rats (c) and SHR (d) from data in (a) and (b), respectively. Values are mean
6 SEM (n = 15).
doi:10.1371/journal.pone.0090339.g004
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L-Carnitine transport in normotensive rats
Several reports describe that the natural amino acid L-carnitine
could act by improving the high arterial blood pressure in patients
with essential hypertension [3,4] and in animal models of
hypertension [5,26]. These results complement the possibility that
in hypertension the membrane transport of this amino acid is
reduced, a phenomenon that is supported by studies showing a
correlation between increased L-carnitine plasma level and higher
blood pressure in adult men [31]. Plasma membrane transport of
L-carnitine is mediated by OCTNs in mammalian cells, and the
isotypes Octn1, Octn2 and Octn3 have been cloned from rats
[12,32]. Our results show that RAECs exhibit TTC mediated by at
least three different components (Na+-dependent (TTCNa+dep), Na
+-
independent (TTCNa+indep) and lineal, nonsaturable transport) in the
range up to 80 mmol/L L-carnitine. These findings agree with the
basic characteristics described for Octn-like transport of this amino
acid in other cell types [33–35]. Since the Eadie-Hofstee
representation of the TTC data was not lineal, it is likely that at
least two or more transport systems acting in parallel [36,37] will
account for L-carnitine transport in RAECs from non-hyperten-
sive rats. In addition, since the TTCNa+dep and
TTCNa+indep
components of transport were lineal in the Eadie-Hofstee plot,
either a single transport system or two or more transport systems
with similar kinetic parameters acting in parallel mediate the Na+-
dependent and the Na+-independent L-carnitine transport in this
cell type.
Our results also show that cells from WKY rats exhibit a TSC
resulting from a pronounced differential contribution of the
TSCNa+dep and the
TSCNa+indep components when the relative Vmax/
Km for these components were compared. The relative contribu-
tion of the Vmax/Km for the
TSCNa+dep component to TSC is lower
(,30%) (from 1/TSC/Na+-depF = 0.30) compared with the
contribution accounted by the TSCNa+indep component (,73%)
(1/TSC/Na+-indepF = 0.73). Thus, a Na+indep component of L-
carnitine transport predominates in RAECs from non-hyperten-
sive WKY rats.
Octn1 is widely expressed in several tissues, including micro-
vascular endothelium from human heart [38], and mediates L-
carnitine transport via a Na+-independent mechanism [34,39]
with apparent Km values ranging from 2–200 mmol/L [13–15].
Since the results of our study show that the apparent Km for the
TSCNa+dep and
TSCNa+indep components (Km = 21–46 mmol/L) was
in the range of values described for this membrane transporter
isoform in other cell types [35], the possibility that Octn1 was
responsible of the Na+-independent L-carnitine transport in
RAECs from WKY rats is supported. However, Octn2-mediated
transport of L-carnitine is described as a Na+-dependent transport
mechanism with higher affinity (Km = 2–20 mmol/L) compared to
Octn1 [16,18–22]. Octn2 is also expressed in other types of
endothelial cells, including human heart and brain capillaries
endothelium [23,40]; therefore Octn2 could also account for the
Na+-dependent transport of L-carnitine in RAECs. Interestingly,
since the plasma concentration of L-carnitine for WKY rats is
reported as 20–36 mmol/L [41] it is likely that the lower affinity
transport system Octn1 would play a preferential role compared
with Octn2, which is likely to be saturated at physiological L-
carnitine plasma concentrations, in maintaining the extracellular
physiological concentrations of this amino acid in these animals.
In the present study, both Octn1 and Octn2 mRNA expression
was detected in RAECs from WKY rats. Interestingly, Octn2
mRNA relative expression resulted to be ,31 fold higher
compared with Octn1 mRNA in these cells. Since the relative
contribution of the TSCNa+dep component to the Vmax/Km for TSC
was ,30%, it is likely that not more than ,10 fold change in
Octn2 mRNA expression (estimated from the (Octn2 mRNA/
Octn1 mRNA)/(1/TSC/Na+-depF) ratio) could sustain a TSCNa+dep
component for the TSC in RAECs. The remaining transport
mediated via a TSCNa+indep component (,73%) could represents
the contribution of a Na+-independent transport activity derived
from Octn1 in this cell type. Interestingly, since the contribution
for the Na+-dependent Octn2 transport is reported as ,3 fold
higher than the transport detected in the absence of extracellular
Na+ in other cell types [42], an equivalent fractional contribution
for these components to L-carnitine transport in RAECs from
WKY rats could be expected. However, the latter seems unlikely
in this cell type since the relative contribution of the TSCNa+dep
component to the Vmax/Km for TSC was ,30% (1/TSC/Na+-depF
= 0.3) compared with ,73% (1/TSC/Na+-indepF = 0.73) for the
TSCNa+indep component. Thus, contrasting with other cell types
[35,42], these findings further support the possibility that the
Na+indep component predominates (,2.4 fold) compared with the
Na+dep component regarding their contribution to TSC. This could
be interpreted as a major contribution of Octn1 compared with
Octn2 to the saturable transport of L-carnitine in RAECs from
WKY rats.
L-Carnitine transport in RAECs from WKY rats was also
dependent on the pHo, a characteristic well described for Octn1
[13,32] and Octn2 [43]. Our results show that TSC was increased
by ,20% by alkalization of the extracellular medium, an effect
resulting from a combined increases in the TSCNa+indep component
(,58%) and decreases in the TSCNa+dep component (,29%). This
phenomenon could be due to a higher sensitivity to alkalization of
the TSCNa+dep [(TSC SE50) minus (
TSCNa+dep IE50) = 0.26 units of
pHo] compared with the
TSCNa+indep [(TSC SE50) minus
(TSCNa+indep IE50) = 0.50 units of pHo] components regarding
the change seen in TSC. Based in these findings, a higher
alkalization-dependent increase in the TSC could be reached
whether these two transport components were equally altered or
whether the TSCNa+indep component was unaltered by this
environmental condition. Interestingly, the increase of TSC caused
by a change of 0.6 units of pHo in RAECs was ,3.3 fold the
increase reported for 150 mmol/L tetraethylammonium (TEA)
uptake in response to a similar change in pHo units in HEK293
cells expressing the human OCTN1 form [13]. However,
Figure 5. Expression of Octn1 and Octn2. The relative mRNA
expression level of Octn1 and Octn2 in RAECs cultures from WKY rats or
SHR was estimated from the 22DDCT method using the Light CyclerH
480 SW 1.5 relative quantification (delta-delta-Ct) study software as
described in Methods. Gene expression levels were normalized to
GAPDH mRNA level. *P,0.05 versus corresponding values for Octn2.
{P,0.02 versus corresponding values in SHR. Values are mean 6 SEM
(n = 15).
doi:10.1371/journal.pone.0090339.g005
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contrasting with these results a larger increase in the pHo value (1
unit of pHo) reduced overall transport of TEA in these cells [32].
Thus, it is likely that OCTNs-like transport is differentially
responsive to the degree of alkalization reached in HEK293 cells.
Interestingly, a change in ,0.4 units of pHo has been shown to
increase the activity of other membrane transport systems, such as
the sodium/proton exchanger isoform 1 in MDCK cells [44],
suggesting that modulation of Octn1/2 by a similar change in the
pHo in RAECs agree with what is reported in other cell types. On
the other hand, acidification of the extracellular pHo does not alter
TSC, a net effect that result from a proportional reduced TSCNa+dep
and increased TSCNa+indep transport components. Interestingly the
effect of extracellular acidification was similar for both compo-
nents, suggesting that these components are equally sensitive to
acidification in RAECs from WKY rats. Thus, acidification and
alkalization of extracellular medium results in a differential
modulation of L-carnitine transport in RAECs from non-
hypertensive rats.
Effect of spontaneous hypertension on L-carnitine
transport
Cells from SHR exhibit a semisaturable TTC unaffected by a
lineal, non-saturable component in the range of L-carnitine
concentrations used in this study. This data was best fitted to a
first-order regression line in an Eadie-Hofstee plot, suggesting that
one or more transport systems with apparent Km values in the
same range could mediate L-carnitine transport in RAECs from
SHR. The apparent Km values for L-carnitine transport by RAECs
in SHR were similar to values detected in non-hypertensive rats,
and within the range of the plasma L-carnitine concentration
reported in SHR (21–41 mmol/L) [41]. Thus, L-carnitine
transport via Octn1/2 could contribute to maintain the physio-
logical plasma concentration of this amino acid in SHR. Our
results also show that TTC is mainly mediated by a TTCNa+indep
(,75%) with a minor contribution of TTCNa+dep (,25%) compo-
nents. These findings agree with those obtained by contrasting the
relative Vmax/Km for these components with that for TSC. Since
Figure 6. Effect of extracellular pH on saturable transport of L-carnitine, and rat aorta reactivity. Total saturable transport of L-carnitine
(Total), and the Na+-dependent (Na+dep) and Na
+-independent (Na+indep) transport components (20 mmol/L L-carnitine, 3 mCi/mL L-[3H]carnitine, 30
seconds, 37uC) in RAECs cultures from WKY rats (a) or SHR (b) exposed to culture medium with the pH adjusted to different values. (c) Relaxation of
32.5 mmol/L KCl preconstricted endothelium-intact aortic vessel rings (With endothelium) from WKY rats or SHR in response to increasing
concentrations of calcitonine gene related peptide (CGRP, 5 minutes), in the absence (-Car) or presence (+Car) of 20 mmol/L L-carnitine (30 minutes).
(d) Relaxation of endothelium-denuded aortic vessel rings (Without endothelium) to CGRP as in (c). *P,0.05 versus all other values for the
corresponding components. Values are mean 6 SEM (n = 4–10).
doi:10.1371/journal.pone.0090339.g006
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the relative contribution of the Vmax/Km for the
TSCNa+indep
component is higher (,75%) (1/TSC/Na+-indepF = 0.75) compared
with the contribution accounted by the TSCNa+dep component
(,30%) (1/TSC/Na+-depF = 0.30), and considering that similar
findings were found for the vi values for these transport
components, it is suggested that RAECs from SHR exhibit
saturable transport of L-carnitine where the Na+-independent
transport predominates by ,2.5 fold compared with the Na+-
dependent. This result is ,2.1 fold higher compared with cells
from non-hypertensive rats supporting the possibility that hyper-
tension could associate with a higher requirement of Na+-
independent transport of L-carnitine via Octn1/2 activity in
RAECs. Thus, it is likely that a deficiency in the TSCNa+dep
component results in RAECs dysfunction in SHR. This would not
be explained by a lower Vmax/Km of the
TSCNa+dep component,
since the relative contribution of this component to TSC in these
cells was similar to that in cells from non-hypertensive rat
((1/TSC/Na+-depF in WKY rats)/(1/TSC/Na+-depF in SHR = 1.01).
In addition, the relative contribution of the TSCNa+dep component
compared with the TSCNa+indep component to TSC in SHR is also
similar to non-hypertensive rats ((1/Na+-indep/Na+-depF in WKY
rats)/(1/Na+-indep/Na+-depF in SHR = 1.03). Thus, reduced overall
transport of L-carnitine in RAECs from SHR could be mainly due
to reduced expression of the Na+-dependent Octn2 and in a less
extend to a reduced expression of the Na+-independent Octn1
membrane transporters. In fact, the Octn2 mRNA expression in
cells from SHR is only 2.6 fold compared with Octn1 mRNA
expression, a value that is largely minor compared with the 31 fold
increase for this mRNA detected in cells from non-hypertensive
rats. Thus, a reduced Octn2 expression without alterations in the
Vmax/Km could account for the reduced
TSCNa+dep component of
L-carnitine transport in RAECs from SHR.
Interestingly, as found in cells from non-hypertensive rats, the
relative contribution of the TSCNa+dep component to the Vmax/Km
for TSC was ,30%. Thus, a proportional change by Octn2
expression to (i.e., ,1.48 fold) would sustain the TSCNa+dep
component of the saturable transport activity in RAECs from
SHR. Interestingly, this value is ,85% lower compared with the
potential requested change in Octn2 mRNA expression in cells
from non-hypertensive rats. Therefore, SHR is a pathological
condition that results in lower request of Octn2 mRNA expression
compared with RAECs from non-hypertensive rats. The results
also show that L-carnitine transport in RAECs from SHR was
dependent on the pHo, supporting the possibility that transport
was mediated by Octn1/2 in this cell type. In this case, alkalization
of the extracellular medium resulted in reduced TSC, which was
due to reduced Na+indep component. This finding is different from
RAECs from non-hypertensive rats, suggesting that alkalization
could result in a differential down-regulation of L-carnitine
transport in RAECs from SHR compared with non-hypertensive
rats. However, since the Na+indep component of transport was also
reduced in cells from non-hypertensive rats, it is likely that
sensitivity of this component to a change in the pHo is similar in
cells from SHR and WKY rats.
In conclusion, the kinetic parameters of L-carnitine transport in
RAECs from SHR and non-hypertensive WKY rats were
characterized. The overall saturable transport was mediated by
Na+indep and Na
+
dep components, with the latter being crucial in the
reduced maximal transport capacity detected in cells from SHR.
The kinetic parameters, pHo- and Na
+-dependency of transport
suggest that Octn1 and Octn2 are likely responsible for membrane
transport of L-carnitine in endothelial cells from the aorta of SHR
and WKY rats. These results are the first characterizing the kinetic
parameters for the membrane transport mechanisms of L-
carnitine in rat aortic endothelium from non-hypertensive WKY
and spontaneously hypertensive rats. Furthermore, since (a) the
reactivity of aortic rings to the endothelium-dependent vasodilator
CGRP was reduced in preparations from SHR compared with
WKY rats, (b) L-carnitine supplementation in vitro restored CGRP
vasodilation to values in vessels from normotensive rats, and (c)
CGRP was ineffective in endothelium-denuded rat aortic rings, it
is suggested that restoration of a functional endothelium could
result from bioavailability of L-carnitine to the aorta endothelium
in the spontaneously hypertensive animals.
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